Five years experience of prescribing milnacipran: An interview with Didier Papeta (Head of Psychiatry, General Military Hospital, Brest, France).
The serotonin and noradrenaline reuptake inhibitor (SNRI), milnacipran, has been available in France for over 5 years. Although many of the published clinical trials were, at least partially, carried out in France, there has been little feedback in the medical literature concerning the everyday use of milnacipran in this country. In contrast to the tradition in some countries, the publication of case reports in French medical journals is not common. In order to get a feedback from day-to-day use of a compound it is therefore necessary to carry out use surveys which are expensive and time-consuming. In the absence of such surveys personal opinions forged over several years by extensive prescribers of a compound can give valuable insight, albeit with the risks of bias and of being non-representative.